Two Routes To Higher Prices
Our first bullish trade is on a business generating substantial cash and returning capital to shareholders. Our second has a clinical readout due this quarter that could change how investors value its lead drug. Today’s alert puts both opportunities into asymmetric option structures.
The first came from Tuesday’s Portfolio Armor Top Names: the stocks our system estimates will have the highest returns over the next six months, net of hedging costs.
The candidate combines commercial PC revenue growth, cash generation and a fresh technical-screen pass.
A Catalyst Can Change The Valuation
The second came from our Multibaggers list, a tracked group of outside analysts selected for multiple recent stock winners of 100% or more. One of those analysts has made a bullish case for a biotech approaching a clinical milestone.
The readout will test its lead drug against placebo. We’re betting on an efficacy signal that could lift the pipeline’s value.
The two option structures help finance bullish exposure while keeping the entry risk defined. We priced both using Tuesday’s closing stock prices and Cboe’s contract-specific implied volatilities.
Full details including the company names, complete option structures, maximum entry prices and pre-set exit orders are below.
New to our alerts? Start here for an overview of our approach:
Today’s Top Names Trade
Theme: PC revenue growth and cash returns support upside.
RSI: 46; Chartmill Technical Rating: 6; Setup Rating: 7; Fundamental Rating: 5.
